Skip to main content
Premium Trial:

Request an Annual Quote

DNA Sequencing Firm Element Biosciences Closes $276M Series C Financing Round

NEW YORK – DNA sequencing technology firm Element Biosciences said on Tuesday that it has closed a $276 million Series C financing round.

New investors Janus Henderson Investors, Logos Capital, Meritech Capital Partners, Morgan Stanley's Counterpoint Global, and T. Rowe Price joined existing investors Fidelity Management & Research, Foresite Capital, JS Capital Management, RA Capital Advisors, and Venrock for this round.

Proceeds from the financing will be used to scale the firm's commercial organization and to fund the launch of its next-generation sequencing platform.

"Element has developed a differentiated, modular, platform-based approach that reinvents all aspects of a DNA sequencing solution," said John Stuelpnagel, chairman of the firm's board of directors, in a statement. "The company has the vision and executional roadmap needed to support current and emerging opportunities in the genomics research market."

The round brings Element's total fundraising to approximately $400 million. The San Diego-based firm raised $80 million in Series B financing in January 2020.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.